356 related articles for article (PubMed ID: 10734180)
1. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
[TBL] [Abstract][Full Text] [Related]
3. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
Underwood DC; Bochnowicz S; Osborn RR; Kotzer CJ; Luttmann MA; Hay DW; Gorycki PD; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):988-95. PubMed ID: 9864284
[TBL] [Abstract][Full Text] [Related]
4. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways.
Birrell MA; Wong S; McCluskie K; Catley MC; Hardaker EL; Haj-Yahia S; Belvisi MG
J Pharmacol Exp Ther; 2006 Mar; 316(3):1318-27. PubMed ID: 16368902
[TBL] [Abstract][Full Text] [Related]
5. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor of p42/44 mitogen-activated protein kinase, but not p38 MAPK, attenuated antigen challenge of guinea pig airways in vitro.
Chue SC; Seow CJ; Duan W; Yeo KS; Koh AH; Wong WS
Int Immunopharmacol; 2004 Aug; 4(8):1089-98. PubMed ID: 15222984
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
8. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
Underwood DC; Osborn RR; Bochnowicz S; Webb EF; Rieman DJ; Lee JC; Romanic AM; Adams JL; Hay DW; Griswold DE
Am J Physiol Lung Cell Mol Physiol; 2000 Nov; 279(5):L895-902. PubMed ID: 11053025
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
10. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia.
Chialda L; Zhang M; Brune K; Pahl A
Respir Res; 2005 Apr; 6(1):36. PubMed ID: 15833106
[TBL] [Abstract][Full Text] [Related]
12. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
13. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
15. Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor.
Kobayashi H; Yoshida R; Kanada Y; Fukuda Y; Yagyu T; Inagaki K; Kondo T; Kurita N; Suzuki M; Kanayama N; Terao T
J Periodontal Res; 2005 Dec; 40(6):461-8. PubMed ID: 16302924
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro cytokine modulatory activity of newly synthesised 2-aminotetraline derivatives.
Ruggiero V; Piovesan P; Fabrizi C; Lauro GM; Campo S; Albertoni C; Nucera E; Carminati P; Ghirardi O
Shock; 2004 Jan; 21(1):77-85. PubMed ID: 14676688
[TBL] [Abstract][Full Text] [Related]
17. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
[TBL] [Abstract][Full Text] [Related]
18. CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.
Ciallella JR; Saporito M; Lund S; Leist M; Hasseldam H; McGann N; Smith CS; Bozyczko-Coyne D; Flood DG
Eur J Pharmacol; 2005 May; 515(1-3):179-87. PubMed ID: 15904918
[TBL] [Abstract][Full Text] [Related]
19. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Schafer PH; Siekierka JJ
J Med Chem; 1998 Oct; 41(22):4196-8. PubMed ID: 9784093
[No Abstract] [Full Text] [Related]
20. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.
Underwood DC; Osborn RR; Novak LB; Matthews JK; Newsholme SJ; Undem BJ; Hand JM; Torphy TJ
J Pharmacol Exp Ther; 1993 Jul; 266(1):306-13. PubMed ID: 8392555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
